Lannett Company

Lannett Co., Inc. engages in the development, manufacture, marketing, and distribution of generic pharmaceutical products. It offers products in different forms including capsules, tablets, liquids, powders, and sprays. The company was founded in 1942 and is headquartered in Trevose, PA.

Earnings data Q1 2023

Earnings data Q2 2023

Carvana

ElectroCore Inc

Genius Brands

Marathon Digital Holdings

Rocket Companies, Inc.

Getty Images Holdings Inc

With major economic weakness possibly lurking around the corner, investors should consider targeting stocks to sell. Specifically, market participants should note securities that feature rising short borrow fees.

7 Stocks to Sell as Borrowing Costs Rise

Lannett Company, Inc. (NYSE:LCI ) Q2 2023 Earnings Conference Call February 1, 2023 4:30 PM ET Company Participants Robert Jaffe - Investor Relations Tim Crew - Chief Executive Officer John Kozlowski - Chief Financial Officer Operator Greetings and welcome to the Lannett Company Fiscal 2023 Second Quarter Financial Results Conference Call. [Operator Instructions] As a reminder, this conference is being recorded.

Lannett Company, Inc. (LCI) Q2 2023 Earnings Call Transcript

Lannett (LCI) delivered earnings and revenue surprises of 17.07% and 10.84%, respectively, for the quarter ended December 2022. Do the numbers hold clues to what lies ahead for the stock?

Lannett (LCI) Reports Q2 Loss, Tops Revenue Estimates

Q2 Business and Financial Highlights: Net Sales were $80.9 Million Gross Margin was 18%, Adjusted Gross Margin was 19% Net Sales, Gross Margin and Adjusted Gross Margin Up Versus Preceding Two Quarters $19 Million Income Tax Refund Received, Cash Balance of $56 Million at December 31 st Pipeline Updates: Pivotal Biosimilar Insulin Glargine Clinical Trial Top-line Results Anticipated in Current Quarter; BLA Filing Targeted for Middle of Calendar 2023 Positive Results from Study of Biosimilar Insulin Aspart vs US NovoLog®; Commencement of Pivotal Trial Anticipated by Fall of Current Year Executed Sub-License Agreement Related to Insulin Pen Delivery Device, Improving Ability to Freely Market Insulin Products Upon Approval Generic FLOVENT ® DISKUS ® ANDA Filing Anticipated by Mid Year TREVOSE, Pa. , Feb. 1, 2023 /PRNewswire/ -- Lannett Company, Inc. (NYSE: LCI) today reported financial results for its fiscal 2023 second quarter ended December 31, 2022.

LANNETT REPORTS IMPROVED FISCAL 2023 SECOND QUARTER FINANCIAL RESULTS; RAISES FULL-YEAR GUIDANCE

TREVOSE, Pa. , Jan. 25, 2023 /PRNewswire/ -- Lannett Company, Inc. (NYSE: LCI) today announced that its Board of Directors approved a 1-for-4 reverse stock split of its issued and outstanding shares of common stock, effective at 5 p.m.

LANNETT ANNOUNCES 1 FOR 4 REVERSE STOCK SPLIT

TREVOSE, Pa. , Jan. 25, 2023 /PRNewswire/ -- Lannett Company, Inc. (NYSE: LCI) today announced that it will report financial results for its fiscal 2023 second quarter on Wednesday, February 1, 2023, after the market closes.

LANNETT TO REPORT FISCAL 2023 SECOND-QUARTER FINANCIAL RESULTS, HOST CONFERENCE CALL ON WEDNESDAY, FEBRUARY 1

--Announces Positive Animal PK Study Results of Insulin Aspart Versus US NovoLog®-- --Analysis of Pivotal Trial Results of Insulin Glargine Nearly Completed,  BLA Filing Timeline Slightly Delayed, But Potential Launch Timing Remains in Range-- TREVOSE, Pa. , Jan. 4, 2023 /PRNewswire/ -- Lannett Company, Inc. (NYSE: LCI) today provided an update on the clinical advancement and development of its biosimilar insulin aspart and biosimilar insulin glargine products.

LANNETT PROVIDES DEVELOPMENT UPDATE ON BIOSIMILAR INSULIN PRODUCTS

TREVOSE, Pa. , Nov. 7, 2022 /PRNewswire/ -- Lannett Company, Inc. (NYSE: LCI) today announced that it has entered into an agreement with Ypsomed AG, the manufacturer and supplier of the pen injector device to be used in connection with its biosimilar insulin glargine and biosimilar insulin aspart development programs, that will provide a patent sublicense to the company and its strategic alliance partner within the HEC Group of companies (HEC).

LANNETT ANNOUNCES PATENT LICENSES FOR THE PEN INJECTOR DELIVERY DEVICE TO BE USED FOR ITS INSULIN GLARGINE AND INSULIN ASPART DEVELOPMENT PROGRAM

Lannett (LCI) delivered earnings and revenue surprises of 8.70% and 10.05%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?

Lannett (LCI) Reports Q1 Loss, Tops Revenue Estimates

Lannett Company, Inc. (NYSE:LCI ) Q1 2023 Earnings Conference Call November 2, 2022 4:30 PM ET Company Participants Robert Jaffe - Investor Relations Tim Crew - Chief Executive Officer John Kozlowski - Chief Financial Officer Conference Call Participants Scott Henry - ROTH Capital Operator Thank you for standing by. This is the conference operator.

Lannett Company, Inc. (LCI) Q1 2023 Earnings Call Transcript

Q1 Business and Financial Highlights: Net Sales were $75.1 Million Gross Margin 17%, Adjusted Gross Margin 18% Net Sales, Gross Margin and Adjusted Gross Margin Increased from Preceding Quarter Cash Was $78 Million at September 30 Sold Several Discontinued ANDAs for Approximately $3 Million Pipeline Updates: Completed Dosing of Subjects in the Pivotal Biosimilar Insulin Glargine Clinical Trial, Top-line Results Anticipated by Year End; BLA Filing On Track for First Half of 2023; Generic FLOVENT ® DISKUS ® ANDA Filing Anticipated Spring of Next Year, Earlier Granted CGT Status by FDA TREVOSE, Pa. , Nov. 2, 2022 /PRNewswire/ -- Lannett Company, Inc. (NYSE: LCI) today reported financial results for its fiscal 2023 first quarter ended September 30, 2022.

LANNETT REPORTS BETTER THAN EXPECTED FINANCIAL RESULTS FOR FISCAL 2023 FIRST-QUARTER; REITERATES FULL-YEAR GUIDANCE

TREVOSE, Pa. , Oct. 26, 2022 /PRNewswire/ -- Lannett Company, Inc. (NYSE: LCI) today announced that it will report financial results for its fiscal 2023 first quarter on Wednesday, November 2, 2022, after the market closes.

LANNETT TO REPORT FISCAL 2023 FIRST-QUARTER FINANCIAL RESULTS, HOST CONFERENCE CALL ON WEDNESDAY, NOVEMBER 2

--Approval Allows Site to Rapidly Expand Liquid Drug Manufacturing-- PHILADELPHIA , Oct. 21, 2022 /PRNewswire/ -- Lannett Company, Inc. (NYSE: LCI) today announced that it has received approval from the US Food and Drug Administration (FDA) to manufacture Numbrino®, the company's branded topical anesthetic product, at its main plant in Seymour, Indiana. The company previously manufactured Numbrino and other liquid drug products at its Carmel, New York plant, which it sold in March of this year as part of a restructuring and cost reduction plan.

LANNETT RECEIVES FDA APPROVAL TO MANUFACTURE NUMBRINO® AT SEYMOUR PLANT

-Companies Entered Into a Separate Private Label Agreement for Certain Other Lannett Generic Products- PHILADELPHIA , Oct. 19, 2022 /PRNewswire/ -- Lannett Company, Inc. (NYSE: LCI) today announced that it has recently sold previously discontinued abbreviated new drug applications (ANDAs) for approximately $3 million to a privately held pharmaceutical company. The transaction was structured as a sale of assets.

LANNETT ANNOUNCES SALE OF SEVERAL DISCONTINUED GENERIC DRUGS

No Reported Serious Adverse Events; Topline Results Expected Later This Year TREVOSE, Pa. , Aug. 31, 2022 /PRNewswire/ -- Lannett Company, Inc. (NYSE: LCI) today announced that subject dosing has been completed in the pivotal clinical trial of biosimilar insulin glargine, a product the company is co-developing with its strategic alliance partners within the HEC Group of companies (HEC).

LANNETT ANNOUNCES SUBJECT DOSING COMPLETE FOR PIVOTAL CLINICAL TRIAL OF BIOSIMILAR INSULIN GLARGINE

Lannett Company, Inc. (NYSE:LCI ) Q4 2022 Earnings Conference Call August 24, 2022 4:30 PM ET Company Participants Robert Jaffe - Investor Relations, Robert Jaffe Co., LLC Timothy Crew - Chief Executive Officer John Kozlowski - Chief Financial Officer Conference Call Participants Scott Henry - ROTH Capital Partners, LLC Operator Hello, and welcome to the Lannett Company's Fiscal 2022 Fourth Quarter and Full Year Financial Results Conference Call. [Operator Instructions] As a reminder, this conference is being recorded.

Lannett Company, Inc. (LCI) CEO Timothy Crew on Q4 2022 Results - Earnings Call Transcript

Q4 Business and Financial Highlights: Net Sales were $74.2 Million Adjusted Gross Margin Better than Expected, Improved vs Q3 Cash Was $88 Million at June 30 Completed Major Elements of November 2021 Restructuring Plan Pipeline Updates: Pivotal Biosimilar Insulin Glargine Clinical Trial Over 90% Complete, Top-line Results Anticipated by Year End; BLA Filing On Track for First Half of 2023 Expect to File IND for Biosimilar Insulin Aspart by First Half of 2023 Generic FLOVENT ® DISKUS ® Product On Track for ANDA Filing Early Next Calendar Year, Granted CGT Status by FDA Expect Partner to Commence Pilot PK Trials for Generic Spiriva ® Handihaler ® by Year End 2022 Licensed a Filed ANDA for Mesalamine Delayed Release Tablets USP, 1.2 g, from an Existing Partner Expect to Launch At Least Four Non-Solid Oral Generic Products With Limited Competition in Fiscal 2023 TREVOSE, Pa. , Aug. 24, 2022 /PRNewswire/ -- Lannett Company, Inc. (NYSE: LCI) today reported financial results for its fiscal 2022 fourth quarter and full year ended June 30, 2022.

LANNETT REPORTS FISCAL 2022 FOURTH-QUARTER, FULL-YEAR FINANCIAL RESULTS

TREVOSE, Pa. , Aug. 19, 2022 /PRNewswire/ -- Lannett Company, Inc. (NYSE: LCI) today announced that it will report financial results for its fiscal 2022 fourth quarter and full year on Wednesday, August 24, 2022, after the market closes.

LANNETT TO REPORT FISCAL 2022 FOURTH-QUARTER, FULL-YEAR FINANCIAL RESULTS, HOST CONFERENCE CALL ON WEDNESDAY, AUGUST 24

Approximately Half of the Planned Number of Subjects Have Received the First Dose, With No Reported Serious Adverse Events Study Progressing On Schedule Topline Results Expected Later This Year TREVOSE, Pa. , June 1, 2022 /PRNewswire/ -- Lannett Company, Inc. (NYSE: LCI) today provided an update on its ongoing pivotal clinical trial of biosimilar insulin glargine, a product the company is co-developing with its strategic alliance partners within the HEC Group of companies (HEC).

LANNETT PROVIDES UPDATE ON PIVOTAL CLINICAL TRIAL FOR BIOSIMILAR INSULIN GLARGINE

-- Current Drug Market Shortage Exists for Fludarabine Phosphate, An Injectable Chemotherapeutic Medication; Marketing Anticipated to Commence Later This Calendar Year --  PHILADELPHIA, May 12, 2022 /PRNewswire/ -- Lannett Company, Inc. (NYSE: LCI) today announced that it has entered into an agreement with Areva Pharmaceuticals to be the exclusive U.S. distributor of Fludarabine Phosphate for injection, USP, 50 mg/2mL, single dose vials. "Fludarabine Phosphate for injection represents a continuation of our push to new dosage forms with attractive market opportunities," said Tim Crew, chief executive officer of Lannett.

LANNETT ENTERS AGREEMENT TO BE EXCLUSIVE U.S. DISTRIBUTOR OF FLUDARABINE PHOSPATE FOR INJECTION, USP

Lannett Company, Inc. (NYSE:LCI ) Q3 2022 Earnings Conference Call May 4, 2022 4:30 PM ET Company Participants Robert Jaffe - Investor Relations, Robert Jaffe Co., LLC Timothy Crew - Chief Executive Officer John Kozlowski - Chief Financial Officer Conference Call Participants Scott Henry - ROTH Capital Partners, LLC Operator Welcome to Lannett Company's Fiscal 2022 Third Quarter Financial Results Conference Call. At this time, all participants are in a listen-only mode.

Lannett Company, Inc. (LCI) CEO Timothy Crew on Q3 2022 Results - Earnings Call Transcript

Lannett (LCI) delivered earnings and revenue surprises of 4.65% and 6.33%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?

Lannett (LCI) Reports Q3 Loss, Lags Revenue Estimates

Q3 Business and Financial Highlights: Net Sales were $78.4 Million Cash in Excess of $106 Million at March 31 Completed Sale of Liquid Manufacturing Plant for $10.5 Million; Major Elements of November 2021 Restructuring Plan Expected to be Completed by June 30 Pivotal Biosimilar Insulin Glargine Clinical Trial Progressing TREVOSE, Pa. , May 4, 2022 /PRNewswire/ -- Lannett Company, Inc. (NYSE: LCI) today reported financial results for its fiscal 2022 third quarter ended March 31, 2022.

LANNETT REPORTS FISCAL 2022 THIRD-QUARTER FINANCIAL RESULTS

TREVOSE, Pa. , April 27, 2022 /PRNewswire/ -- Lannett Company, Inc. (NYSE: LCI) today announced that it will report financial results for its fiscal 2022 third quarter on Wednesday, May 4, 2022, after the market closes.

LANNETT TO REPORT FISCAL 2022 THIRD-QUARTER FINANCIAL RESULTS, HOST CONFERENCE CALL ON WEDNESDAY, MAY 4

--First Patient Dosed, Topline Study Results Expected Later This Year; Potential BLA Filing in Early 2023 and Launch in the First Half of 2024-- TREVOSE, Pa. , March 29, 2022 /PRNewswire/ -- Lannett Company, Inc. (NYSE: LCI) today announced that it has initiated the pivotal clinical trial of biosimilar insulin glargine, a product the company is co-developing with its strategic alliance partners within the HEC Group of companies (HEC).

News for Lannett Company Stock (LCI)